We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research
News

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research
News

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced that the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) has selected Genedata Expressionist® as the bioinformatics platform for pharmacogenomics- and oncology-related translational research. IKP, one of the premier clinical research facilities in Germany, focuses on improved patient care through personalized medicine. Developing biomarkers that predict drug efficacy as well as drug toxicity, IKP research drives treatment decisions that bring the right drugs to the right patients.

Genedata Expressionist provides IKP with a comprehensive software platform to process, interpret, and manage terabytes of transcriptomics, genomics, epigenomics, and clinical data from next-generation sequencing (NGS), microarrays, and qPCR experiments. IKP collaborates with Genedata to further develop and customize Genedata Expressionist to meet specific requirements of organizing and integrating omics data from numerous clinical studies. The collaboration will further focus on the development of analytical workflows that identify driver mutations associated with poor drug response or prognosis.

"With the number of clinical studies employing next-generation technologies rapidly increasing and advancing, we face the challenge of organizing, integrating, and interpreting massive amounts of genomic data combined with a large variety of clinical information," said Prof. Dr. med. Matthias Schwab, head of IKP Stuttgart. "Genedata Expressionist provides a comprehensive platform that allows us to efficiently extract the most relevant scientific and clinical insights from our experiments. It is particularly important for us that Genedata Expressionist covers all aspects of NGS data management and analysis, from raw data to results."

Taking NGS Experiments from Research to Clinical Applications
Genedata Expressionist is an oncology-focused enterprise-level software solution. Its data integration capabilities allow researchers to enrich their experiments with genomics data from a wide range of public data repositories.

Used by several leading pharmaceutical companies, Genedata Expressionist helps researchers find new drug targets, develop biomarkers for drug response and drug toxicity, and identify new indications or combination therapies for existing drugs. It is an integral tool for interdisciplinary oncology teams requiring audit and reporting facilities and enables oncologists to easily share, store, and publish results while ensuring data integrity.

"We are excited about our collaboration with the IKP, a global leader in developing advanced personalized medicine approaches for better patient care," noted Dr. Othmar Pfannes, CEO of Genedata. "We are committed to investing in personalized medicine applications and partnerships that help us to continuously innovate data processing and ultimately make Genedata Expressionist the system of choice for translation research in oncology."

Advertisement